Pacira BioSciences

Contributing Author

Recent Articles by Pacira BioSciences

Dec-03	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PCRX GlobeNewswire
Dec-02	Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera Compared to Radiofrequency Ablation in Chronic Low Back Pain PCRX GlobeNewswire
Nov-26	Pacira BioSciences Files EXPAREL Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical PCRX GlobeNewswire
Nov-11	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences PCRX GlobeNewswire
Nov-06	Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance PCRX GlobeNewswire
Nov-05	Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee PCRX GlobeNewswire
Nov-04	Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control PCRX GlobeNewswire
Oct-30	Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 PCRX GlobeNewswire
Oct-28	Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee PCRX GlobeNewswire
Oct-27	Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL PCRX GlobeNewswire
Oct-23	Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL PCRX GlobeNewswire
Oct-21	Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL PCRX GlobeNewswire
Oct-20	Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy PCRX GlobeNewswire
Oct-03	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PCRX GlobeNewswire
Sep-05	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PCRX GlobeNewswire
Aug-05	Pacira BioSciences Reports Second Quarter 2025 Financial Results PCRX GlobeNewswire
Jul-24	Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 PCRX GlobeNewswire
Jul-22	Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts PCRX GlobeNewswire
Jul-03	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PCRX GlobeNewswire
Jun-18	Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient's Journey to Pain Relief and Innovation in Care at BIO 2025 PCRX GlobeNewswire
Jun-11	Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee PCRX GlobeNewswire
Jun-05	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PCRX GlobeNewswire
May-15	Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee PCRX GlobeNewswire
May-14	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences PCRX GlobeNewswire
May-08	Pacira BioSciences Reports First Quarter 2025 Financial Results PCRX GlobeNewswire
May-06	Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis PCRX GlobeNewswire
May-02	Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis PCRX GlobeNewswire

Pacira BioSciences

Recent Articles by Pacira BioSciences

Upgrade your FINVIZ experience